Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million...

Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5
Million to iSonix LLC

FARMINGDALE, N.Y., April 7 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq:
MSON), a developer of minimally invasive ultrasonic medical device technology,
which in Europe is used for the ablation of tumors and worldwide for other
acute health conditions, announced that it has sold its Ultrasonic Laboratory
business for $3.5 million in cash to iSonix LLC. The Ultrasonic Laboratory
business manufactures and markets scientific and industrial ultrasonic
equipment and recorded approximately $4.6 million in revenue in Fiscal 2008.

Michael A. McManus, Jr., President and Chief Executive Officer, stated, "We
are pleased to further strengthen our balance sheet with the additional $3.5
million in cash from the sale of a non-core business. We expect to use the
proceeds to pay down some of our bank debt, increase our working capital and
other general corporate purposes. We also believe the transaction speaks to
the underlying value of our businesses that we believe has not been reflected
in our market capitalization today. Most importantly, this transaction also
emphasizes our commitment to continue our growth initiatives and become a
focused medical device company."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets
therapeutic ultrasonic medical devices and laboratory equipment. Misonix's
therapeutic ultrasonic platform is the basis for several innovative medical
technologies. Addressing a combined market estimated to be in excess of $3
billion annually; Misonix's proprietary ultrasonic medical devices are used
for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery,
and other surgical and medical applications. Additional information is
available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

Investor Relations Contact:
Cameron Associates, Inc.
Kevin McGrath
212-245-4577
Kevin@cameronassoc.com

SOURCE Misonix, Inc.

Richard Zaremba, Misonix, Inc., +1-631-694-9555, invest@misonix.com, or
Investor Relations, Kevin McGrath, Cameron Associates, Inc., +1-212-245-4577,
Kevin@cameronassoc.com